Organization
Epworth Healthcare
7 abstracts
Abstract
The potential role of serial circulating tumor DNA (ctDNA) testing after upfront surgery to guide adjuvant chemotherapy for early stage pancreatic cancer: The AGITG DYNAMIC-Pancreas trial.Org: Northern Health, Peter MacCallum Cancer Centre, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, VIC, Australia,
Abstract
Mutated KRAS as a promising target in pancreas cancer: PURPLE registry data to inform real-world incidence and prognostic significance and to aid trial recruitment.Org: Northern Health, Peter MacCallum Cancer Centre, Melbourne, Australia, Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne Health,
Abstract
Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: Overall survival and updated 5-year results from the randomized DYNAMIC trial.Org: Department of Medical Oncology, Peter MacCallum Cancer Centre and Personalised Oncology Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins University School of Medicine, Baltimore, MD, Melanoma Institute Australia, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia, Center for Cancer Prevention and Early Detection, City of Hope, Phoenix, AZ, Eastern Health & Epworth Healthcare & Eastern Health Clinical School, Monash University, Melbourne, Australia,
Abstract
Circulating tumor DNA (ctDNA) as a marker of residual disease and recurrence in resected stage I-IV epithelial ovarian cancer (EOC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Epworth Healthcare, Western Health, Walter and Eliza Hall Institute of Medical Research, University of Melbourne,
Abstract
Patterns of ovarian cancer care in an elderly population in Australia: A prospective cohort study from the National Gynaecology Oncology Registry (NGOR).Org: Monash University School of Public Health and Preventive Medicine, Cancer Research Program, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Women's Hospital, Epworth Healthcare,
Abstract
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.Org: Sorbonne University and Saint-Antoine Hospital, Hôpital Saint-Antoine, INSERM UMRs938, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,
Abstract
Comparison of BRCA genetic testing and subsequent treatment with PARP inhibitors (PARPi) for ederly vs non-elderly women with non-mucinous epithelial ovarian cancer (EOC): A large prospective cohort study from the Australian National Gynaecology Oncology Registry (NGOR).Org: Monash University School of Public Health and Preventive Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia, The Royal Women's Hospital, Epworth Healthcare, Monash University School of Public Health and Preventive Medicine and Department of Medical Oncology, Alfred Health,